Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 1176 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Orexigen Q1 revenues soar

The company has reported a net loss of $11.6m, or $0.24 loss per diluted share, compared to a net loss of $14.08m, or $0.30 loss per diluted share,

Netsmart appoints new CEO

Valentine will succeed James Conway, who is retiring after 15 years as CEO at Netsmart. Prior to Netsmart, Valentine worked for Cerner Corporation as the executive vice president

Novavax Q1 revenues up

The company has reported a net loss of $7.45m, or $0.07 loss per diluted share, compared to net loss of $10.34m or $0.10 loss per diluted share, for

BAL30072 effective against superbugs: Basilea

BAL30072 is a novel siderophore (iron-binding) sulfactam antibiotic conferring potent bactericidal activity against Gram-negative pathogens. NDM-1 is an enzyme that leads to resistance towards antibiotics that have been

PolyPid introduces new family of drug carriers

The patented carrier can be tailored to small molecules, peptides, protein and nucleic acids-based drugs. The PolyPid platform can be utilized to address numerous medical indications in various

GTx Q1 revenues fall

The company has reported a net loss of $2.6m, or $0.05 loss per diluted share, compared to net income of $44.34m or $1.22 per diluted share, for the